Ginkgo Bioworks continues to face a weak demand environment, which has contributed to a lack of growth in recent years. Learn ...

Protein large language model (LLM) designed to help enterprises accelerate drug development coming to Google Cloud's Vertex AI Model Garden soon; one of the first-of-its-kind in the industry Model API ...

Ginkgo Bioworks announces the launch of Ginkgo Datapoints, which aims to make the training of AI models easier and more efficient. Ginkgo Bioworks shares are up more than 9% over the past week. Get 5 ...

Ginkgo is embarking on a cost-cutting plan that could pave the path to profitability and share performance. The main bear case against Ginkgo is there's no compelling reason to buy the stock right now ...

Ginkgo's share price remains under pressure, despite the business stabilizing in Q2. Ginkgo's shift away from downstream value sharing has undermined the company's bull case, which could be hard for ...

Ginkgo's future may be promising, but whether the company can realize its potential is debatable. Special purpose acquisition companies (SPACs) were popular in 2021 while investors were buying up meme ...

Ginkgo Bioworks reported quarterly sales of $38 million which missed the analyst consensus estimate of $46.044 million by 17.47% and is a 52.91% decrease in sales year-over-year. The company said the ...

To say the past year has been rough for investors in Ginkgo Bioworks (NYSE: DNA) would be an understatement of the highest order. As of Aug 14, shares of the synthetic-biology stock were down by 86% ...

Diving headfirst into the generative artificial intelligence market, Ginkgo Bioworks said on Tuesday it plans to develop its own AI models for drug development and other synthetic biology applications ...

Ginkgo Bioworks (NYSE: DNA) went public a few years ago. With sky-high expectations for growth spanning multiple industries, it may have been tempting for investors to take a chance on the ...